These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 30014684)

  • 1. Anti-TNFα-induced psoriasis under treatment of hidradenitis suppurativa: report of 2 cases.
    Musumeci ML; Nasca MR; Pavone A; Micali G
    G Ital Dermatol Venereol; 2020 Jun; 155(3):377-379. PubMed ID: 30014684
    [No Abstract]   [Full Text] [Related]  

  • 2. Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab.
    Nuño-González A; Dehesa L; Ricotti C; Kerdel F
    Actas Dermosifiliogr; 2012 Dec; 103(10):936-7. PubMed ID: 23149048
    [No Abstract]   [Full Text] [Related]  

  • 3. Paradoxical psoriasiform reactions to antitumour necrosis factor-α drugs in hidradenitis suppurativa.
    Dequidt L; Cogrel O; Guillet S; Milpied B; Darrigade AS; Beylot-Barry M; Pham-Ledard A
    Br J Dermatol; 2018 Jan; 178(1):281-283. PubMed ID: 28444990
    [No Abstract]   [Full Text] [Related]  

  • 4. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
    Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
    Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
    Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
    Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squamous Cell Carcinoma in Hidradenitis Suppurativa Lesions Following Tumor Necrosis Factor α Inhibitors.
    Cooper SD; Cowdrey MCE; Linos KD; Lefferts JA; Basic KK
    Cutis; 2021 Apr; 107(4):E5-E7. PubMed ID: 34096852
    [No Abstract]   [Full Text] [Related]  

  • 7. Update on TNF Inhibitors in Dermatology.
    Sobell JM
    Semin Cutan Med Surg; 2016 Jun; 35(6 Suppl):S104-6. PubMed ID: 27537073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches.
    Tampouratzi E; Kanni T; Katsantonis J; Douvali T
    F1000Res; 2019; 8():2002. PubMed ID: 33456757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis Onset during Anti-TNF Treatment for Hidradenitis Suppurativa: Successful Remission of Both Conditions with Secukinumab.
    Kontochristopoulos G; Kanni T; Marnelakis I; Agiasofitou E; Liakou A; Rigopoulos D
    Skinmed; 2023; 21(1):57-58. PubMed ID: 36987833
    [No Abstract]   [Full Text] [Related]  

  • 10. A case series of tumor necrosis factor inhibitor-induced psoriasis in patients with hidradenitis suppurativa.
    Kelly KA; Edminister J; Pichardo RO; Feldman SR
    Dermatol Online J; 2022 Dec; 28(6):. PubMed ID: 36809103
    [No Abstract]   [Full Text] [Related]  

  • 11. Antidrug antibodies to tumour necrosis factor inhibitors in hidradenitis suppurativa: a systematic review.
    Lu JD; Milakovic M; Piguet V; Alavi A
    Br J Dermatol; 2021 Mar; 184(3):555-557. PubMed ID: 33006769
    [No Abstract]   [Full Text] [Related]  

  • 12. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
    Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    Clin Exp Dermatol; 2020 Oct; 45(7):859-865. PubMed ID: 32358868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
    Brunasso AM; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):70-1. PubMed ID: 21103830
    [No Abstract]   [Full Text] [Related]  

  • 15. Adherence to TNF-alpha inhibitors in patients with hidradenitis suppurativa.
    Thomsen SF; Sand FL
    J Dermatolog Treat; 2015 Feb; 26(1):97-8. PubMed ID: 24552476
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hidradenitis suppurativa. Response to treatment with infliximab].
    Pedraz J; Daudén E; Pérez-Gala S; Goiriz-Valdés R; Fernández-Peñas P; García-Diez A
    Actas Dermosifiliogr; 2007 Jun; 98(5):325-31. PubMed ID: 17555675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases.
    Fougerousse AC; Reguiai Z; Roussel A; Bécherel PA;
    J Am Acad Dermatol; 2020 Jul; 83(1):199-201. PubMed ID: 32151626
    [No Abstract]   [Full Text] [Related]  

  • 18. Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure.
    Melendez-Gonzalez MDM; Hamad J; Sayed C
    J Invest Dermatol; 2021 Dec; 141(12):2975-2979. PubMed ID: 34097922
    [No Abstract]   [Full Text] [Related]  

  • 19. "Paradoxical joint inflammation" possibly induced by a tumor necrosis factor antagonist in three patients with psoriasis.
    Di Costanzo L; Ferrucci MG; Cusano F
    G Ital Dermatol Venereol; 2020 Jun; 155(3):370-371. PubMed ID: 30636393
    [No Abstract]   [Full Text] [Related]  

  • 20. Anti-TNF-α therapy modulates mTORC1 signalling in hidradenitis suppurativa.
    Balato A; Caiazzo G; Annunziata MC; Marasca C; Scala E; Cacciapuoti S; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):e43-e45. PubMed ID: 29956847
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.